2022版美国儿科学会新生儿高胆红素血症管理指南解读

杨静丽; 王建辉

doi:10.7499/j.issn.1008-8830.2210119

PDF(981 KB)

中国当代儿科杂志 ›› 2023, Vol. 25 ›› Issue (1) : 11-17. DOI: 10.7499/j.issn.1008-8830.2210119

指南解读

2022版美国儿科学会新生儿高胆红素血症管理指南解读

杨静丽, 王建辉

作者信息 +

Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants

YANG Jing-Li, WANG Jian-Hui

Author information +

文章历史 +

摘要

2022年9月美国儿科学会更新了胎龄≥35周新生儿高胆红素血症管理指南，该指南在整理总结过去18年循证证据的基础上，对胎龄≥35周新生儿高胆红素血症的预防、风险评估、干预及随访等内容进行了更新，现就核心要点进行解读，旨在安全地降低胆红素脑病的风险及不必要的干预风险。

Abstract

The American Academy of Pediatrics updated the guidelines for the management of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks in September 2022. Based on the evidence over the past 18 years, the guidelines are updated from the aspects of the prevention, risk assessment, intervention, and follow-up of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks. This article gives an interpretation of the key points in the guidelines, so as to safely reduce the risk of bilirubin encephalopathy and unnecessary intervention.

导出引用

杨静丽, 王建辉. 2022版美国儿科学会新生儿高胆红素血症管理指南解读[J]. 中国当代儿科杂志. 2023, 25(1): 11-17 https://doi.org/10.7499/j.issn.1008-8830.2210119

YANG Jing-Li, WANG Jian-Hui. Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants[J]. Chinese Journal of Contemporary Pediatrics. 2023, 25(1): 11-17 https://doi.org/10.7499/j.issn.1008-8830.2210119

参考文献

1 Olusanya BO, Teeple S, Kassebaum NJ. The contribution of neonatal jaundice to global child mortality: findings from the GBD 2016 study[J]. Pediatrics, 2018, 141(2): e20171471. PMID: 29305393. DOI: 10.1542/peds.2017-1471.
2 Olusanya BO, Kaplan M, Hansen TWR. Neonatal hyperbilirubinaemia: a global perspective[J]. Lancet Child Adolesc Health, 2018, 2(8): 610-620. PMID: 30119720. DOI: 10.1016/S2352-4642(18)30139-1.
3 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2004, 114(1): 297-316. PMID: 15231951. DOI: 10.1542/peds.114.1.297.
4 中华医学会儿科学分会新生儿学组, 《中华儿科杂志》编辑委员会. 新生儿高胆红素血症诊断和治疗专家共识[J]. 中华儿科杂志, 2014, 52(10): 745-748. DOI: 10.3760/cma.j.issn.0578-1310.2014.10.006.
5 Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058859. PMID: 35927462. DOI: 10.1542/peds.2022-058859.
6 Hynes S, Moore Z, Patton D, et al. Accuracy of transcutaneous bilirubin versus serum bilirubin measurement in preterm infants receiving phototherapy: a systematic review[J]. Adv Neonatal Care, 2020, 20(6): E118-E126. PMID: 32366804. DOI: 10.1097/ANC.0000000000000738.
7 Yang ST, Liu FC, Chen HL. Comparison of transcutaneous and serum bilirubin before, under, and after phototherapy in term and late-preterm infants[J]. Kaohsiung J Med Sci, 2019, 35(11): 715-724. PMID: 31436020. DOI: 10.1002/kjm2.12121.
8 Maisels MJ, Ostrea EM, Touch S, et al. Evaluation of a new transcutaneous bilirubinometer[J]. Pediatrics, 2004, 113(6): 1628-1635. PMID: 15173483. DOI: 10.1542/peds.113.6.1628.
9 Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants[J]. Pediatrics, 2014, 134(2): e340-e345. PMID: 25049352. DOI: 10.1542/peds.2013-4299.
10 Riskin A, Tamir A, Kugelman A, et al. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia?[J]. J Pediatr, 2008, 152(6): 782-787. PMID: 18492516. DOI: 10.1016/j.jpeds.2007.11.003.
11 Setia S, Villaveces A, Dhillon P, et al. Neonatal jaundice in Asian, white, and mixed-race infants[J]. Arch Pediatr Adolesc Med, 2002, 156(3): 276-279. PMID: 11876673. DOI: 10.1001/archpedi.156.3.276.
12 Kuzniewicz MW, Park J, Niki H, et al. Predicting the need for phototherapy after discharge[J]. Pediatrics, 2021, 147(5): e2020019778. PMID: 33903163. DOI: 10.1542/peds.2020-019778.
13 Maisels MJ, Deridder JM, Kring EA, et al. Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia[J]. J Perinatol, 2009, 29(9): 612-617. PMID: 19421200. DOI: 10.1038/jp.2009.43.
14 Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1): 154-168. PMID: 27429428. DOI: 10.1097/MPG.0000000000001334.
15 Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements[J]. JAMA, 2020, 323(12): 1141-1150. PMID: 32207797. PMCID: PMC7093763. DOI: 10.1001/jama.2020.0837.
16 Slaughter JL, Kemper AR, Newman TB. Technical report: diagnosis and management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058865. PMID: 35927519. DOI: 10.1542/peds.2022-058865.
17 Wickremasinghe AC, Risley RJ, Kuzniewicz MW, et al. Risk of sensorineural hearing loss and bilirubin exchange transfusion thresholds[J]. Pediatrics, 2015, 136(3): 505-512. PMID: 26283777. DOI: 10.1542/peds.2014-3357.
18 Wu YW, Kuzniewicz MW, Wickremasinghe AC, et al. Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study[J]. JAMA Pediatr, 2015, 169(3): 239-246. PMID: 25560920. DOI: 10.1001/jamapediatrics.2014.3036.
19 Das RR, Naik SS. Neonatal hyperbilirubinemia and childhood allergic diseases: a systematic review[J]. Pediatr Allergy Immunol, 2015, 26(1): 2-11. PMID: 25229699. DOI: 10.1111/pai.12281.
20 Newman TB, Wu YW, Kuzniewicz MW, et al. Childhood seizures after phototherapy[J]. Pediatrics, 2018, 142(4): e20180648. PMID: 30249623. DOI: 10.1542/peds.2018-0648.
21 Bugaiski-Shaked A, Shany E, Mesner O, et al. Association between neonatal phototherapy exposure and childhood neoplasm[J]. J Pediatr, 2022, 245: 111-116. PMID: 35120988. DOI: 10.1016/j.jpeds.2022.01.046.
22 Maisels MJ, Kring E. Rebound in serum bilirubin level following intensive phototherapy[J]. Arch Pediatr Adolesc Med, 2002, 156(7): 669-672. PMID: 12090833. DOI: 10.1001/archpedi.156.7.669.
23 Lamola AA. A pharmacologic view of phototherapy[J]. Clin Perinatol, 2016, 43(2): 259-276. PMID: 27235206. DOI: 10.1016/j.clp.2016.01.004.
24 Chang PW, Waite WM. Evaluation of home phototherapy for neonatal hyperbilirubinemia[J]. J Pediatr, 2020, 220: 80-85. PMID: 32067781. DOI: 10.1016/j.jpeds.2020.01.004.
25 Chang PW, Newman TB. A simpler prediction rule for rebound hyperbilirubinemia[J]. Pediatrics, 2019, 144(1): e20183712. PMID: 31196939. DOI: 10.1542/peds.2018-3712.
26 Wolf MF, Childers J, Gray KD, et al. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia[J]. J Perinatol, 2020, 40(10): 1506-1512. PMID: 32152492. PMCID: PMC8021453. DOI: 10.1038/s41372-020-0642-0.
27 Watchko JF. Emergency release uncross-matched packed red blood cells for immediate double volume exchange transfusion in neonates with intermediate to advanced acute bilirubin encephalopathy: timely but insufficient?[J]. J Perinatol, 2018, 38(8): 947-953. PMID: 29997396. DOI: 10.1038/s41372-018-0168-x.